Currency In USD
| Previous Close | 0.78 |
| Open | 0.78 |
| Day High | 0.79 |
| Day Low | 0.76 |
| 52-Week High | 1.35 |
| 52-Week Low | 0.65 |
| Volume | 11,812 |
| Average Volume | 252,011 |
| Market Cap | 28.28M |
| PE | -3.7 |
| EPS | -0.21 |
| Moving Average 50 Days | 0.77 |
| Moving Average 200 Days | 0.9 |
| Change | -0.01 |
Dyadic to Report 2025 Full Year Financial Results and Host Conference Call on Wednesday, March 25, 2026
GlobeNewswire Inc.
Mar 11, 2026 8:10 PM GMT
JUPITER, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Dyadic International, Inc. d/b/a Dyadic Applied BioSolutions ("Dyadic", "we", "us", "our", or the "Company") (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-
Dyadic and Fermbox Bio Launch First Product Under Expanded Collaboration: Animal-Origin-Free Recombinant DNase I (RNase-Free)
GlobeNewswire Inc.
Mar 04, 2026 12:20 PM GMT
JUPITER, Fla. and BENGALURU, India, March 04, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free proteins a
Dyadic Applied BioSolutions and Inzymes ApS Announce Planned 2026 Commercialization of Non-Animal Dairy Enzyme Following Achievement of Development Milestone
GlobeNewswire Inc.
Mar 02, 2026 12:20 PM GMT
JUPITER, Fla. and COPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Dyadic Applied BioSolutions (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company producing precision-engineered, animal-free protein